Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.

@article{Rech2018RadiotherapyAC,
  title={Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.},
  author={Andrew J. Rech and Hannah Dada and Jonathan J Kotzin and Jorge Henao-Mejia and Andy J. Minn and Christina Twyman-Saint Victor and Robert H. Vonderheide},
  journal={Cancer research},
  year={2018},
  volume={78 15},
  pages={
          4282-4291
        }
}
Immunotherapy in pancreatic ductal adenocarcinoma (PDA) remains a difficult clinical problem despite success in other disease types with immune checkpoint blockade (ICB) and chimeric antigen receptor T-cell therapy. Mechanisms driving immunosuppression and poor T-cell infiltration in PDA are incompletely understood. Here, we use genetically engineered mouse models of PDA that recapitulate hallmarks of human disease to demonstrate that CD40 pathway activation is required for clinical response to… CONTINUE READING
7
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 40 REFERENCES

CD8+ tumoron June 1, 2018

A Fukunaga, M Miyamoto, +3 authors T Oshikiri
  • Pancreas. 2004;28:e26–31
  • 2018

Induction of T-cell on June 1, 2018

R Winograd, KT Byrne, +3 authors DL Bajor
  • Cancer Immunol Res
  • 2018

STING-dependent cytosolic DNA on June 1, 2018

L Deng, H Liang, +3 authors A Arina
  • 2018

Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2017
VIEW 1 EXCERPT

Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2017